Industry News


Aetna Revises Clinical Policy Bulletin on Serum Marker Screening for Down Syndrome

Aetna Inc, Hartford, Conn, recently revised its Clinical Policy Bulletin on Serum Marker Screening for Down Syndrome.

The bulletin was revised to state that Aetna considers measurement of cell-free fetal nucleic acids in maternal blood (eg, MaterniT21 from Sequenom, verifi Prenatal Test from Verinata Health Inc, Harmony Prenatal Test from Ariosa Diagnostics, Panorama Prenatal Test from Natera) medically necessary for testing for fetal aneuploidy (trisomy 13, 18 and 21) in pregnant women with single gestations who meet any of the following indications:

  • Pregnant women age 35 years and older
  • Fetal ultrasonographic findings predicting an increased risk of fetal aneuploidy
  • History of a prior pregnancy with an aneuploidy
  • Positive screening test for an aneuploidy, including first trimester, sequential, or integrated screen, or a positive quadruple screen
  • Parental balanced robertsonian translocation with increased risk for fetal trisomy 13 or trisomy 21

The bulletin was revised to state that measurement of cell-free fetal nucleic acids in maternal blood is experimental and investigational for screening for fetal genotyping for RHD.

Click here for a detailed description from the insurer.

Click here to read CLP‘s women’s health diagnostics products showcase, featuring products noted above.

[Source: Aetna Inc]